Icon (NASDAQ:ICLR – Get Free Report) and Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.
Institutional & Insider Ownership
95.6% of Icon shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 44.0% of Icon shares are held by company insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Icon and Rapid Micro Biosystems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Icon | 5.45% | 7.73% | 4.39% |
| Rapid Micro Biosystems | -145.56% | -177.04% | -73.12% |
Analyst Recommendations
This is a breakdown of recent ratings for Icon and Rapid Micro Biosystems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icon | 1 | 9 | 9 | 1 | 2.50 |
| Rapid Micro Biosystems | 1 | 0 | 2 | 1 | 2.75 |
Icon currently has a consensus target price of $213.76, indicating a potential upside of 9.82%. Rapid Micro Biosystems has a consensus target price of $5.00, indicating a potential upside of 668.05%. Given Rapid Micro Biosystems’ stronger consensus rating and higher possible upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Icon.
Valuation & Earnings
This table compares Icon and Rapid Micro Biosystems”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Icon | $8.25 billion | 1.81 | $229.34 million | $5.81 | 33.50 |
| Rapid Micro Biosystems | $33.59 million | 0.97 | -$47.12 million | ($1.12) | -0.58 |
Icon has higher revenue and earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Icon has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Summary
Icon beats Rapid Micro Biosystems on 11 of the 14 factors compared between the two stocks.
About Icon
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
About Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. develops automated solutions for microbial quality control in regulated manufacturing environments. Its systems are designed to detect and quantify microorganisms more efficiently than traditional manual methods, helping customers improve testing workflows, data integrity, and laboratory productivity. The company’s primary platform, Growth Direct, supports applications including environmental monitoring and rapid microbial testing. The platform combines automated incubation, imaging, detection, and reporting with dedicated consumables, enabling pharmaceutical, biotechnology, medical device, and other manufacturers to monitor contamination risks and evaluate product sterility.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
